Navigation Links
MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
Date:10/10/2007

rmaceutical company committed to the development of new drug candidates and whose current drug candidates include:

-- MCT-125 for the treatment of primary fatigue in MS patients.

-- MCT-175 for the treatment of relapsing-remitting MS.

-- MCT-465 for the treatment of TLR3 positive breast cancers.

-- MCT-475 for the treatment of TLR3 positive cervical cancers.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125, statements regarding selling, using or developing the FA2N-4 cell line and MultiCell's identification of new drug targets. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... and NEW DELHI, India, July 17 ... and the stock market, Daiichi Sankyo,Company, Limited ... (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between ... the largest,controlling shareholders of Ranbaxy, is binding ...
... ST. LOUIS, July 17 SAFC Supply ... of the Sigma-Aldrich Group (Nasdaq:,SIAL), announced today ... initiative,designed specifically to assist its customers with ... (EU) regulation for chemicals --,Registration, Evaluation, Authorization ...
... of bacteria to produce hydrogen in a bioreactor, with the ... an article in the August issue of Microbiology Today, ... be used to scavenge precious metals from spent automotive catalysts ... , Hydrogen has three times more potential energy by weight ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3Fuel from food waste: bacteria provide power 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... identified a new species of mysterious beaked whale based on ... in the Indian and Pacific Oceans over the past 50 ... toothed whales distantly related to sperm whales, are found in ... throughout the world,s oceans. "They are rarely seen at ...
... This news release is available in ... in the body, for instance, during development, or when neurons establish ... ,wrong turn, will generally cause disease or developmental disorders. The cells ... which they then repel after a short period of contact. Among ...
... NY) When the foe is a disease-causing microbe, identifying ... to kill or disable it. Research to gain this ... The Price Family Foundation. The gift to Albert Einstein ... of Oklahoma funds a research collaboration to investigate the structural ...
Cached Biology News:Researchers discover rare new species of deep-diving whale 2Sociable receptors: In pairs, in groups or in a crowd 2Sociable receptors: In pairs, in groups or in a crowd 3Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 2Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 3
... are supplied as 10X concentrated solutions. REact Buffer ... of the REact buffers and one 250 microl ... four 1 ml vials of REact 1 Buffer ... four 1 ml vials of REact 3 Buffer ...
... Apoptosis Assay Kit #4 detects apoptosis ... in the permeability of cell membranes. This ... and propidium iodide nucleic acid stains. YO-PRO-1 ... of apoptotic cells and labels them with ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Biology Products: